Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares traded up 7.5% on Friday . The company traded as high as $0.90 and last traded at $0.86. 1,753,743 shares changed hands during trading, an increase of 258% from the average session volume of 489,758 shares. The stock had previously closed at $0.80.

A number of research analysts recently weighed in on the company. ValuEngine lowered Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Zacks Investment Research lowered Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $5.63.

COPYRIGHT VIOLATION NOTICE: “Cyclacel Pharmaceuticals (CYCC) Trading 7.5% Higher” was first posted by Marea Informative and is owned by of Marea Informative. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.mareainformativa.com/news/2019/03/17/cyclacel-pharmaceuticals-cycc-trading-7-5-higher.html.

About Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Read More: What is intrinsic value?

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.